Fulcrum Therapeutics, Inc. (FULC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.85+0.26%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · FULC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -64.8% |
| Our one-year growth estimate | diamond | 84.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 149.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
FULC — M&A activity — Changes in Control of Registrant
Dated 2026-08-17
Changes in Control of Registrant. To the extent required by this Item, the information included in
Why it matters: Fulcrum's cash runway is critical for its future operations. Changes could impact its strategic options.
Watch forFulcrum's cash position stays stable or improves in Q2 earnings.
Also watch forFulcrum shows a big drop in cash reserves in Q2 earnings.
Why it matters: Keeping cash reserves is important for future work. Changes may show financial problems.
Watch forFulcrum confirms it has enough cash to support operations until 2029.
Also watch forFulcrum reports a big drop in cash reserves that risks the 2029 plan.
Why it matters: The outcome could shape Fulcrum's future plans and actions after stopping pociredir.
Watch forFulcrum shares a clear plan or partnership from the review.
Also watch forNo updates on the review create doubt about the company's future.
Why it matters: The FDA's answer will show what Fulcrum will do with its drug plans.
Worry ifFulcrum gets FDA feedback that may help pociredir move forward.
Less concerning ifFDA feedback confirms stopping pociredir with no way to continue.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$161 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $705 loss on $10,000 · 7.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,849 loss on $10,000 · 78.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The merger will change Fulcrum's focus and money plans, affecting future growth.
Supportive ifThe merger completes in Q4 2026. Fulcrum stockholders will get a cash dividend.
Worry ifThe merger does not close due to problems with rules or shareholders.
Why it matters: The dividend will give quick value to Fulcrum's stockholders and show financial health.
Supportive ifFulcrum will pay a cash dividend of over $20.3 million. This will happen before the merger closes.
Worry ifNo cash dividend is declared prior to the merger closing.
Why it matters: The success of the workforce reduction will impact Fulcrum's cost structure and financial health.
Watch forFulcrum cuts its workforce to 9 employees, saving money as planned.
Also watch forFulcrum does not cut the workforce well, causing higher costs.